Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jun;52(6):702-709.
doi: 10.1016/j.amepre.2017.01.027. Epub 2017 Mar 22.

Use of BRCA Mutation Test in the U.S., 2004-2014

Fangjian Guo  1 , Jacqueline M Hirth  2 , Yu-Li Lin  3 , Gwyn Richardson  2 , Lyuba Levine  2 , Abbey B Berenson  2 , Yong-Fang Kuo  4
Affiliations

Use of BRCA Mutation Test in the U.S., 2004-2014

Fangjian Guo et al. Am J Prev Med. 2017 Jun.

Abstract

Introduction: BRCA mutation testing has been used for screening women at high risk of breast and ovarian cancer and for selecting the best treatment for those with breast cancer. To optimize the infrastructure and medical resources allocation for genetic testing, it is important to understand the use of BRCA mutation testing in the U.S. health system.

Methods: This retrospective cohort study included 53,254 adult women with insurance claims for BRCA mutation testing between 2004 and 2014 from ClinformaticsTM Data Mart Database. Data analysis was performed in 2016. This study assessed trends in the use of BRCA mutation testing in women with previously diagnosed breast or ovarian cancer and those without (unaffected women).

Results: Between 2004 and 2014, of those receiving BRCA testing, the proportion of BRCA tests performed in unaffected women increased significantly (p<0.001), from 24.3% in 2004 to 61.5% in 2014. An increase in the proportion of BRCA tests used in unaffected women was found in each characteristic subgroup. In 2014, most subgroups had a proportion surpassing 50%, except for those aged 51-65 years and those without a family history of breast cancer. There was a much lower proportion of those aged 20-40 years among tested women with previously diagnosed breast or ovarian cancer than in unaffected women (17.6% vs 41.7%, p<0.001).

Conclusions: During the past decade, the role of BRCA testing has gradually shifted from being used primarily in cancer patients to being used in unaffected women in the U.S.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Trends in proportion of unaffected women among women who received BRCA tests, from 2004 to 2014
Notes: A. All women. B. By age groups. C. By region of Residence. D. By family history of breast or ovarian cancer. Data are plotted as proportion (%). The whisker represents the 95% CI. P-values for the tests of the interaction terms between the year of BRCA testing and age, region, and family history of breast or ovarian cancer were all <0.001. 20–40 y: 20–40 years of age. Year: the year when BRCA testing was performed. Unaffected women: women who did not have previously diagnosed breast or ovarian cancer.
See this image and copyright information in PMC

Comment in

References

    1. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994;266(5182):66–71. https://doi.org/10.1126/science.7545954. - DOI - PubMed
    1. Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995;378(6559):789–792. https://doi.org/10.1038/378789a0. - DOI - PubMed
    1. FitzGerald MG, MacDonald DJ, Krainer M, et al. Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer. N Engl J Med. 1996;334(3):143–149. https://doi.org/10.1056/NEJM199601183340302. - DOI - PubMed
    1. Narod SA. BRCA mutations in the management of breast cancer: the state of the art. Nat Rev Clin Oncol. 2010;7(12):702–707. https://doi.org/10.1038/nrclinonc.2010.166. - DOI - PubMed
    1. Alsop K, Fereday S, Meldrum C, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol. 2012;30(21):2654–2663. https://doi.org/10.1200/JCO.2011.39.8545. - DOI - PMC - PubMed